ADMA Biologics (ADMA) Announces Proposed $75M Share Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
ADMA Biologics (ADMA) Prices 23.5M Share Upsized Common Offering at $3.50/Sh
February 7, 2020 6:10 AM ESTADMA Biologics, Inc. (NASDAQ: ADMA) an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases, today announced the pricing of its previously announced underwritten public offering of 23,500,000 shares... More
After-Hours Stock Movers 02/06: (ASRT) (PINS) (UBER) Higher; (ZGNX) (MYGN) (RESN) Lower (more...)
February 6, 2020 6:01 PM ESTAfter-Hours Stock Movers
Assertio Therapeutics, Inc. (NASDAQ: ASRT) 51% HIGHER; entered into a definitive agreement (Agreement) with Collegium Pharmaceutical, Inc. (Nasdaq: COLL) pursuant to which Collegium will acquire the NUCYNTA® franchise of products from the Company. The closing of the agreement is expected by February 14, 2020.
Zogenix, Inc. (NASDAQ: ZGNX) 33% LOWER; reported positive top-line results from its global Phase 3 clinical trial (Study 1601) of its lead investigational therapy, FINTEPLA® (ZX008, fenfluramine oral solution) in... More
ADMA Biologics (ADMA) to Offer $75M in Stock
February 6, 2020 4:09 PM ESTADMA Biologics, Inc. (Nasdaq: ADMA) announced that it has commenced an $75 million underwritten public offering of its common stock. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of... More
